Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Subscribe To Our Newsletter & Stay Updated
